23:11 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Cell culture and mouse studies suggest inhibition of SRF or its co-activator MLK1 could help treat drug-resistant BCC. In one human and two mouse SMO inhibitor-resistant BCC cell lines, a tool...
20:11 , Sep 26, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Insomnia; neurology Mouse studies suggest activation of LHX6-expressing neurons in the ventral zona incerta could help treat sleep disorders. In mice, levels of the activation marker c-fos were higher in LHX6-positive neurons in the ventral...
19:21 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies suggest inhibiting the FOSB/HDAC1 axis could help treat AD. In dentate gyrus tissue samples from a mouse model of AD, levels of a truncated FOSB isoform were higher and levels...
16:41 , Jun 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Cachexia Mouse studies suggest inhibiting CGRP-expressing neurons could help treat cancer-associated anorexia and malaise. In a mouse model of the indication, levels of the neuronal activation marker c-fos were higher in CGRP-expressing parabrachial nucleus neurons...
20:10 , May 25, 2017 |  BC Innovations  |  Translation in Brief

Youthful memories

Alkahest Inc. co-founder and Stanford University researcher Tony Wyss-Coray has followed up his earlier discovery of blood factors in the elderly that contribute to cognitive decline by finding an umbilical cord blood factor that may...
15:49 , Mar 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML) In vitro and mouse studies suggest combining Gleevec imatinib with inhibition of c-fos and DUSP1 could help treat CML. In patient peripheral blood monocytes (PBMCs), levels of c-fos and DUSP1 were...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Skin cancer Not applicable In vitro and mouse studies suggest treating skin inflammation could help treat or...
07:00 , Mar 18, 2013 |  BioCentury  |  Emerging Company Profile

gIcare: Colonoscopy comfort

gIcare pharma Inc. is developing a pipeline of non-sedating colonic analgesic compounds to provide new and lower cost alternatives for pain management during colonoscopy. Sedation during endoscopy has become routine practice among gastroenterologists, even though Medicare...
07:00 , Mar 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Serum response factor (c-fos serum response element-binding transcription factor; SRF) ...
07:00 , Apr 22, 2002 |  BC Week In Review  |  Company News

Toray Industries Inc. other research news

Researchers published in Nature evidence that interferon-beta and c-Fos, which are expressed in response to activation of RANKL (receptor activator of NF-kB ligand), constitute an autoregulatory loop for maintenance of bone homeostasis....